MedTrace Logo

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-10-07

No results posted yet for this study

Summary

This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

DRUG

Acapatamab

Acapatamab will be administered as an intravenous (IV) infusion.

DRUG

Enzalutamide

Enzalutamide will be administered orally.

DRUG

Abiraterone

Abiraterone will be administered orally.

DRUG

AMG 404

AMG 404 will be administered as an intravenous (IV) infusion.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2023-10-23
Completion
2023-10-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631601 on ClinicalTrials.gov